Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways.

Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Blok LJ, Burger CW, Bae-Jump VL.

Reprod Sci. 2011 Sep;18(9):832-41. doi: 10.1177/1933719111398501.

2.

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.

Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL.

Gynecol Oncol. 2012 May;125(2):458-69. doi: 10.1016/j.ygyno.2012.01.009. Epub 2012 Jan 16.

3.

Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells.

Lim DY, Cho HJ, Kim J, Nho CW, Lee KW, Park JH.

BMC Gastroenterol. 2012 Jan 23;12:9. doi: 10.1186/1471-230X-12-9.

4.

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H.

Eur J Cancer. 2011 Jul;47(11):1717-26. doi: 10.1016/j.ejca.2011.02.019. Epub 2011 Mar 28.

PMID:
21450456
5.

Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.

Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D.

Endocr Relat Cancer. 2009 Jun;16(2):429-41. doi: 10.1677/ERC-08-0240. Epub 2009 Jan 19.

6.

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 Mar;95(3):415-23. doi: 10.3324/haematol.2009.010785. Epub 2009 Dec 8.

7.

NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.

Zhang Y, Goodfellow R, Li Y, Yang S, Winters CJ, Thiel KW, Leslie KK, Yang B.

Gynecol Oncol. 2015 Oct;139(1):127-33. doi: 10.1016/j.ygyno.2015.07.098. Epub 2015 Jul 17.

8.

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.

Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ.

Mol Cancer Ther. 2009 May;8(5):1095-105. doi: 10.1158/1535-7163.MCT-08-1171. Epub 2009 Apr 14.

9.

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL.

Gynecol Oncol. 2010 Jan;116(1):92-8. doi: 10.1016/j.ygyno.2009.09.024. Epub 2009 Oct 12.

10.

Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

Xiao L, Yang YB, Li XM, Xu CF, Li T, Wang XY.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1089-99. doi: 10.1007/s00432-009-0756-4. Epub 2010 Jan 20.

PMID:
20087603
11.

Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.

Friedrichs N, K├╝chler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W.

J Pathol. 2008 Dec;216(4):428-39. doi: 10.1002/path.2438.

PMID:
18855347
12.

Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro.

Shu S, Yang Y, Li X, Li T, Zhang Y, Xu C, Liang C, Wang X.

Mol Cell Biochem. 2011 Jul;353(1-2):225-33. doi: 10.1007/s11010-011-0790-9. Epub 2011 Mar 26.

PMID:
21442237
13.
14.

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.

Lung Cancer. 2008 May;60(2):166-74. Epub 2007 Nov 14.

PMID:
18006183
15.

IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma.

Gao L, Wang X, Wang X, Zhang L, Qiang C, Chang S, Ren W, Li S, Yang Y, Tong D, Chen C, Li Z, Song T, Zhi K, Huang C.

Oncotarget. 2014 May 15;5(9):2562-74.

16.
17.

Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.

Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC.

Cancer Res. 2005 Sep 15;65(18):8504-13.

18.

Proliferative and signaling activities of insulin analogues in endometrial cancer cells.

Aizen D, Sarfstein R, Bruchim I, Weinstein D, Laron Z, Werner H.

Mol Cell Endocrinol. 2015 May 5;406:27-39. doi: 10.1016/j.mce.2015.02.011. Epub 2015 Feb 16.

PMID:
25697343
19.

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R.

PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.

20.

Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells.

Wetterau LA, Francis MJ, Ma L, Cohen P.

J Clin Endocrinol Metab. 2003 Jul;88(7):3354-9.

PMID:
12843187

Supplemental Content

Support Center